Daiichi Sankyo: A JPY1 Trillion Growth Engine Meets a Pipeline Reset

ENHERTU and DATROWAY are compounding faster than expected, but I-DXd's accelerated filing is gone, AVANZAR has slipped again, and the CMO bill still lands in the second half.

4568.T · Earnings Call · 2026-10-30

The growth engine is no longer the debate

Daiichi Sankyo's fiscal Q2 was a statement quarter on the top line. Revenue rose 19.7% year over year to JPY1,167.2 billion, core operating profit jumped 46.9% to JPY221.3 billion, and profit attributable to owners climbed 15.8% to JPY151.5 billion. ENHERTU did JPY464.5 billion in global product sales, up 45.9%, and DATROWAY added JPY48.3 billion, up JPY32.6 billion year over year. “ENHERTU delivered another quarter of outstanding performance. Global product sales reached JPY 464.5 billion, an increase of 45.9% year-over-year or JPY 146.1 billion.” — Ken Keller, Head of Global Oncology Business Unit · 2026-10-30 The growth was broad — U.S. up 55%, ASCA up 49%, Japan up 37%, Europe up 26% — which matters because it means the DXd ADCs franchise is no longer a one-market launch story. It is becoming an installed commercial platform. The strategic tell is that Daiichi is reorganizing around that platform. Effective April 2027, the company will operate as one global commercialization organization, collapsing regional businesses and global commercial functions into a single accountability structure. “Effective April 2027, we will operate as one global commercialization organization, bringing our regional businesses and our global commercial functions together under one unified accountability.” — Ken Keller, Head of Global Oncology Business Unit · 2026-10-30 That is a real change, not boilerplate. With more than 20 registrational readouts expected over the next several years, management is trying to move from “we have great assets” to “we can launch them consistently.” The two commercial poles are already visible: triple negative breast cancer is the near-term DATROWAY opportunity, while small cell is where the pipeline promise is being marked to market.

The I-DXd reset is the quarter's real news

The clean growth print obscured a harder pipeline reset. Daiichi voluntarily withdrew the accelerated approval filing for I-DXd in extensive-stage small cell lung cancer in September after discussions with the FDA. The company will now wait for the full Phase III program, which is nearly fully enrolled.

For I-DXd, as you asked around the withdrawal of the accelerated approval approach... the FDA wanted us to continue with our Phase III program, which is almost completed for enrollment. Based on those discussions, we decided to withdraw the I-DXd approach for accelerated approval, and we're advancing with the full Phase III program.
John Tsai, R&D Executive · 2026-10-30

That is a significant negative for the small cell thesis. It also looks worse against the company's own prior messaging. In January, management said the clinical hold had no impact on the filing and that Daiichi was sticking to its original timeline. “There is no impact on such filing. So we are having a discussion with the regulatory authorities in different countries and regions. And we stick to the original time line.” — Unknown Executive, Senior Executive, possibly CEO or CFO · 2026-01-30 Nine months later, the accelerated path is gone. That is the kind of gap between guidance tone and regulatory reality that investors should price, not excuse. AVANZAR has a similar pattern, though the company is handling it more carefully. The first-line lung cancer study is now expected in the first quarter of calendar 2027, after prior calls had already pushed it from late 2025 into 2026. Management stressed that no interim PFS analysis was conducted and that the futility boundary was passed. “We have not conducted any PFS interims in this trial. This is an exception to the rule of disclosure of interims.” — John Tsai, R&D Executive · 2026-10-30 The prior explanation was less reassuring: “First, regarding AVANZAR, enrollment has been complete. And with the event -- with the incidence of event, we understand that there has been change made, and that's all we know.” — Unknown Executive, Senior Executive, possibly CEO or CFO · 2026-01-30 The market is now being asked to trust an event-driven readout in a blinded trial. That may be fine, but it is not the same as de-risked.

The CMO bill and the governance cleanup

The other recurring overhang is CMO compensation. In Q2, the charge came to JPY4.3 billion, down JPY16.7 billion year over year because of FX adjustments and reversals of prior provisions. But the big number is still ahead: JPY80 billion related to calendar 2028 is expected in Q3 or later, with management leaning toward Q4. “As of now, more heavy as a matter of probability in the fourth quarter, but the key is to the CMOs, the 2028 manufacturing plan.” — Tomohiro Kodama, Finance Executive · 2026-10-30 That timing matters because Q4 is also when a large ENHERTU sales milestone lands — more than JPY90 billion, per the CFO — so the second-half profit split will look ugly even if the full-year total is intact. This is not a new problem; it has been a recurring feature of Daiichi's calls. What is new is that the growth in ENHERTU and DATROWAY is now large enough to absorb it without breaking the full-year guidance. There was also a quieter governance item. Management disclosed that it submitted partial corrections to FY2025 financial results on July 31, 2026, after errors in data aggregation. The company said no structural issues were found in the overall internal control system, but the board is treating it as a warning sign rather than an isolated event. That is the right tone. For a company asking investors to underwrite a multi-year launch cycle, financial-reporting credibility is part of the product.

What management stopped talking about — and what it started

The keyword migration is revealing. A quarter ago, the call was dominated by the small cell filing, the triple negative breast cancer launch, and CMO compensation. This quarter, the new language is CNS activity, ovarian cancer, and combination with ivonescimab. DATROWAY's brain-metastasis data at ESMO — median CNS progression-free survival of 9.5 months versus 2.6 months for chemotherapy — is being positioned as a differentiator. The Summit collaboration adds a PD-1/VEGF combination arm to the DATROWAY story, starting with first-line triple-negative breast cancer. And the ovarian program now spans multiple REJOICE studies, with REJOICE-Ovarian01 showing a 49.7% confirmed response rate at the 5.6 mg/kg dose. At the same time, the old biomarker debate around NMR and the discontinued Claudin 6 program have fallen out of the conversation. That is not necessarily bad — the company is narrowing its narrative to commercial assets and near-term readouts — but it does mean the “next DXd” story is now more concentrated in DATROWAY and the ovarian franchise than the earlier breadth of the pipeline suggested. The stock had no tape context in this dataset, so the call has to stand on its own. On the fundamentals, it does: revenue is compounding, the ENHERTU franchise is deepening, and the global commercialization reset is a credible response to scale. On the pipeline, it is messier: I-DXd's accelerated path is gone, AVANZAR is later again, and the CMO bill still hits the second half. The quarter is a reminder that Daiichi Sankyo is no longer a “promise” story. It is a commercial oncology company with a real growth engine and a real execution risk — and the market will now price both.